MERUS BV

NASDAQ: MRUS (Merus N.V.)

最近更新时间: 07 Mar, 4:40AM

46.10

-0.19 (-0.41%)

前收盘价格 46.29
收盘价格 46.00
成交量 459,783
平均成交量 (3个月) 634,265
市值 3,185,071,872
价格/销量 (P/S) 79.29
股市价格/股市净资产 (P/B) 4.76
52周波幅
37.77 (-18%) — 61.61 (33%)
利润日期 6 May 2025 - 12 May 2025
营业利益率 (TTM) -969.93%
稀释每股收益 (EPS TTM) -3.35
季度收入增长率 (YOY) 2.20%
总债务/股东权益 (D/E MRQ) 1.53%
流动比率 (MRQ) 6.53
营业现金流 (OCF TTM) -185.84 M
杠杆自由现金流 (LFCF TTM) -123.22 M
资产报酬率 (ROA TTM) -27.47%
股东权益报酬率 (ROE TTM) -42.88%

市场趋势

短期 中期
行业 Biotechnology (US) 混合的 混合的
Biotechnology (全球的) 混合的 混合的
股票 Merus N.V. 看跌 看涨

AIStockmoo 评分

1.3
分析师共识 4.0
内部交易活动 -1.5
价格波动 2.0
技术平均移动指标 2.5
技术振荡指标 -0.5
平均 1.30

相关股票

股票 市值 DY P/E(TTM) P/B
MRUS 3 B - - 4.76
ARGX 36 B - 46.31 6.47
TLX 6 B - 185.67 17.15
WVE 1 B - - 7.34
VRTX 127 B - - 8.02
ALNY 33 B - - 493.41

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

部门 Healthcare
行业 Biotechnology
投资方式 Mid Growth
内部持股比例 2.04%
机构持股比例 106.49%
52周波幅
37.77 (-18%) — 61.61 (33%)
目标价格波幅
70.00 (51%) — 109.00 (136%)
109.00 (Guggenheim, 136.44%) 购买
84.00 (82.21%)
70.00 (B of A Securities, 51.84%) 购买
平均值 86.20 (86.99%)
总计 5 购买
平均价格@调整类型 44.84
公司 日期 目标价格 调整类型 价格@调整类型
Guggenheim 28 Mar 2025 109.00 (136.44%) 购买 44.61
18 Mar 2025 109.00 (136.44%) 购买 46.39
B of A Securities 10 Mar 2025 70.00 (51.84%) 购买 46.75
HC Wainwright & Co. 03 Mar 2025 85.00 (84.38%) 购买 45.47
Needham 28 Feb 2025 83.00 (80.04%) 购买 47.09
Piper Sandler 13 Feb 2025 84.00 (82.21%) 购买 40.30
名称 平均购买 ($) 平均卖出 ($) 总净额 总净值 ($)
SHUMAN HARRY - 47.24 -4,000 -188,960
累积净数量 -4,000
累积净值 ($) -188,960
累积平均购买 ($) -
累积平均卖出 ($) 47.24
名称 持有人 日期 类型 数量 价格 价值 ($)
SHUMAN HARRY 职员 21 Mar 2025 卖 (-) 4,000 47.24 188,960
SHUMAN HARRY 职员 21 Mar 2025 执行期权 3,000 - -
日期 类型 细节
01 Apr 2025 公告 Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
01 Apr 2025 公告 Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference
27 Feb 2025 公告 Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
27 Feb 2025 公告 Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update
25 Feb 2025 公告 Merus to Present at Upcoming Investor Conferences
25 Feb 2025 公告 Merus to Present at Upcoming Investor Conferences
18 Feb 2025 公告 Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
18 Feb 2025 公告 Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
13 Feb 2025 公告 Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
13 Feb 2025 公告 Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit
05 Feb 2025 公告 New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
05 Feb 2025 公告 New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer
12 Jan 2025 公告 Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
12 Jan 2025 公告 Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票